Enhancement of the antitumour activity of 5-fluorouracil (5-FU) by inhibiting dihydropyrimidine dehydrogenase activity (DPD) using 5-chloro-2,4-dihydroxypyridine (CDHP) in human tumour cells.
The DOI matches its Crossref record; 31 of the 40 references it cites were found in a registry or an index.
Abstract
The purpose of this study was to evaluate the use of 5-chloro-2,4-dihydroxypyridine (CDHP), a potent inhibitor of dihydropyrimidine dehydrogenase (DPD), to enhance the antitumour activity of the fluoropyrimidines. In an in vitro study, CDHP did not influence cell proliferation by itself. However, CDHP did inhibit 5-fluorouracil (5-FU) degradation and enhanced 5-FU cytotoxicity in a concentration-dependent manner in two human tumour cell lines (MIAPaCa-2 and HuTu80) with relatively high basal DPD activity. CDHP exhibited a maximum effect at a molar ratio (CDHP:5-FU) of more than 0.2. However, CDHP did not have any effect on 5-FU cytotoxicity in the CAL27 tumour cell line, which has a relatively low basal DPD activity, even at concentrations where the DPD activity is almost completely inhibited. In an in vivo study, the maximal tolerable doses (MTD) of tegafur (FT) and a combination of FT and CDHP at a molar ratio of 1:0.4 (FT/CDHP) for nude mice were determined by oral administration for 14 consecutive days. After a single oral administration of either FT or FT/CDHP at the MTD, the 5-FU serum concentration-time profiles were almost the same for both treatment strategies. When nude mice bearing subcutaneous (s.c.) MIAPaCa-2 cells were treated with either FT or FT/CDHP at the MTD, the FT/CDHP treatment showed a significantly higher antitumour effect than the FT treatment (tumour growth inhibition: FT/CDHP, 51+/-12%; FT, 21+/-25%; P<0.05). However, the host-body weight suppression induced by FT/CDHP and FT was equivalent. These findings suggest that the combination of fluoropyrimidine and CDHP for the treatment of tumours with a high basal DPD elicits a greater antitumour effect than treatment with fluoropyrimidines alone and we suggest that CDHP inhibits the degradation of 5-FU in the tumour.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“In addition, studies have reported that DPD inhibitors such as 5-ethynyluracil and 5-chloro-2,4-dihydroxypyridine (CDHP) can improve the anti-tumor activity of 5-FU to a greater extent [100,101,102].”
From Drug Resistance in Colorectal Cancer: From Mechanism to Clinic (2022) · cites this paper as [102]
Citations
Cites
Chou, T.-C., & Talalay, P. (1984) · Advances in Enzyme Regulation · doi:10.1016/0065-2571(84)90007-4 · Cited by 7,178 · cited 1×
“Based on the median effect equation according to Chou and Talalay [24], IC50 values were estimated from the regression line of log–logit plots of concentration versus growth inhibition rate.”
MethodCarmichael, J., DeGraff, W., Gazdar, A. F., Minna, J. D., & Mitchell, J. B. (1987) · PubMed · Cited by 4,198
Salonga, D. S., Danenberg, K. D., Johnson, M. R., Metzger, R., Groshen, S. G., Tsao-Wei, D. D., Lenz, H.-J., Leichman, C. G., Leichman, L., Diasio, R. B., et al. (2000) · PubMed · Cited by 829
Shirasaka, T., Shimamato, Y., Ohshimo, H., Yamaguchi, M., Kato, T., Yonekura, K., & Fukushima, M. (1996) · Anti-Cancer Drugs · doi:10.1097/00001813-199607000-00010 · Cited by 820 · cited 3×
“10), is mainly distributed in the gastrointestinal (GI) tract after oral administration in rats, leading to the relief of the GI toxicity induced by 5-FU [3,8].”
BackgroundSelf-citationHuman pancreatic carcinoma (mia paca‐2) in continuous culture: Sensitivity to asparaginase
Yunis, A. A., Arimura, G. K., & Russin, D. J. (1977) · International Journal of Cancer · doi:10.1002/ijc.2910190118 · Cited by 373
Shirasaka, T., Nakano, K., Takechi, T., Satake, H., Uchida, J., Fujioka, A., Saitô, H., Okabe, H., Oyama, K., Takeda, S., et al. (1996) · PubMed · Cited by 370
Self-citationShirasaka, T., Shimamoto, Y., & Fukushima, M. (1993) · PubMed · Cited by 348
Self-citationEtienne, M. C., Chéradame, S., Fischel, J. L., Formento, P., Dassonville, O., Renée, N., Schneider, M., Thyss, A., Demard, F., & Milano, G. (1995) · Journal of Clinical Oncology · doi:10.1200/jco.1995.13.7.1663 · Cited by 281 · cited 1×
“Etienne and colleagues were the first to discuss the clinical relationship between intratumoral DPD levels and the antitumour effect of 5-FU [9].”
BackgroundEnzymes of uracil catabolism in normal and neoplastic human tissues.
Naguib, F. N. M., el Kouni, M. H., & Cha, S. (1985) · PubMed · Cited by 277
Tatsumi, K., Fukushima, M., Shirasaka, T., & Fujii, S. (1987) · PubMed · Cited by 260
Self-citation
Research works printed but not linked: 5
- Hoff, 1999, Dihydropyrimidine dehydrogenase inhibitory fluoropyrimidines, Semin. Oncol., 26, 52
- Carmichael, 1987, Evaluation of a tetrazolium-based semiautomated colorimetric assay, Cancer Res., 47, 936
- Cao, 1995, 5-Ethynyluracil (776C85), Cancer Res., 55, 6227
- Cao, 1994, 5-Ethynyluracil (776C85), Cancer Res., 54, 1507
- Nagayama, 1997, Disposition of components of new anti-cancer drug S-1 (7), Xenobio Metabol. Dispos., 12, 645
Cited by
5-fluorouracil and other fluoropyrimidines in colorectal cancer: Past, present and future
Vodenkova, S., Buchler, T., Cervena, K., Veskrnova, V., Vodicka, P., & Vymetalkova, V. (2020) · Pharmacology & Therapeutics · doi:10.1016/j.pharmthera.2019.107447 · Cited by 956
Mammalian target of rapamycin, a molecular target in squamous cell carcinomas of the head and neck
Amornphimoltham, P., Patel, V., Sodhi, A., Nikitakis, N. G., Sauk, J. J., Sausville, E. A., Molinolo, A. A., & Gutkind, J. S. (2005) · Cancer Research · doi:10.1158/0008-5472.can-05-0921 · Cited by 238
Oral Anticancer Drugs: Mechanisms of Low Bioavailability and Strategies for Improvement
Stuurman, F. E., Nuijen, B., Beijnen, J. H., & Schellens, J. H. M. (2013) · Clinical Pharmacokinetics · doi:10.1007/s40262-013-0040-2 · Cited by 161
Drug Resistance in Colorectal Cancer: From Mechanism to Clinic
Wang, Q., Shen, X., Chen, G., & Du, J. (2022) · Cancers · doi:10.3390/cancers14122928 · Cited by 160
Drug metabolizing enzymes and their inhibitors' role in cancer resistance
Pathania, S., Bhatia, R., Baldi, A., Singh, R., & Rawal, R. K. (2018) · Biomedicine & Pharmacotherapy · doi:10.1016/j.biopha.2018.05.117 · Cited by 136
Metadata
- Authors
- Takechi, T., Fujioka, A., Matsushima, E., & Fukushima, M.
- Affiliations
- Taiho Pharmaceutical (Japan) (JP)
- Corresponding author
- Takechi, T
- ORCID
- Takechi, T
- Venue
- European Journal of Cancer
- Publisher
- Elsevier BV
- Published
- 2002-06
- Volume
- 38
- Issue
- 9
- Pages
- 1271-1277
- ISSN
- 0959-8049 (ISSN-L)
- OpenAlex
- W2097303718
- Cited by
- 85
- References
- 40
- Citations by year
- 2023: 1 · 2022: 3 · 2021: 1 · 2020: 1 · 2019: 4 · 2018: 4 · 2017: 2 · 2016: 1 · 2015: 4 · 2014: 4 · 2013: 7 · 2012: 5
- FWCI
- 1.39
- Type
- journal article
- Language
- en
- Open access
- closed
- Licence
- www.elsevier.com/tdm/userlicense/1.0/ (tdm)
- Locations
- European Journal of Cancer (publishedVersion)
- PubMed (publishedVersion)
- Topics
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Biochemical and Molecular Research
- Life Sciences › Pharmacology, Toxicology and Pharmaceutics › Pharmacology › Pharmacogenetics and Drug Metabolism
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Cancer therapeutics and mechanisms
- Keywords
- 5-fluorouracil, dihydropyrimidine dehydrogenase, tegafur, antitumour activity, combination chemotherapy, cancer cell lines, MIA PaCa-2 cells
- MeSH terms
- Animals, Drug Interactions, Fluorouracil, Maximum Allowable Concentration, Mice, Inbred BALB C, Neoplasm Transplantation, Oxidoreductases, Pancreatic Neoplasms, Pyridines, Tumor Cells, Cultured, Dihydrouracil Dehydrogenase (NADP), Mice
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Enhancement of the antitumour activity of 5-fluorouracil (5-FU) by inhibiting dihydropyrimidine dehydrogenase activity (DPD) using 5-chloro-2,4-dihydroxypyridine (CDHP) in human tumour cells. https://app.cochat.ai/papers/10.1016/s0959-8049(02)00048-5
- The paper
- Takechi, T., Fujioka, A., Matsushima, E., & Fukushima, M. (2002). Enhancement of the antitumour activity of 5-fluorouracil (5-FU) by inhibiting dihydropyrimidine dehydrogenase activity (DPD) using 5-chloro-2,4-dihydroxypyridine (CDHP) in human tumour cells. European Journal of Cancer. https://doi.org/10.1016/s0959-8049(02)00048-5
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.